AU2008247427A1 - Compositions comprising miR34 therapeutic agents for treating cancer - Google Patents

Compositions comprising miR34 therapeutic agents for treating cancer Download PDF

Info

Publication number
AU2008247427A1
AU2008247427A1 AU2008247427A AU2008247427A AU2008247427A1 AU 2008247427 A1 AU2008247427 A1 AU 2008247427A1 AU 2008247427 A AU2008247427 A AU 2008247427A AU 2008247427 A AU2008247427 A AU 2008247427A AU 2008247427 A1 AU2008247427 A1 AU 2008247427A1
Authority
AU
Australia
Prior art keywords
seq
nucleic acid
strand
nucleotide
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008247427A
Other languages
English (en)
Inventor
Julja Burchard
Michele A. Cleary
Aimee L. Jackson
Lee P. Lim
Peter S. Linsley
Jill F. Magnus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Inpharmatics LLC
Original Assignee
Rosetta Inpharmatics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Inpharmatics LLC filed Critical Rosetta Inpharmatics LLC
Publication of AU2008247427A1 publication Critical patent/AU2008247427A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2008247427A 2007-05-03 2008-05-05 Compositions comprising miR34 therapeutic agents for treating cancer Abandoned AU2008247427A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92762107P 2007-05-03 2007-05-03
US60/927,621 2007-05-03
PCT/US2008/062689 WO2008137867A2 (en) 2007-05-03 2008-05-05 Compositions comprising mir34 therapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
AU2008247427A1 true AU2008247427A1 (en) 2008-11-13

Family

ID=39944228

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008247427A Abandoned AU2008247427A1 (en) 2007-05-03 2008-05-05 Compositions comprising miR34 therapeutic agents for treating cancer

Country Status (6)

Country Link
US (2) US8378088B2 (enExample)
EP (1) EP2152722B1 (enExample)
JP (1) JP2010525826A (enExample)
AU (1) AU2008247427A1 (enExample)
CA (1) CA2686165A1 (enExample)
WO (2) WO2008137862A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005250432B2 (en) 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
JP2010525826A (ja) 2007-05-03 2010-07-29 ロゼッタ インファーマティックス エルエルシー 癌を治療するためのｍｉｒ３４治療剤を含む組成物
JP2010529966A (ja) * 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US8841268B2 (en) * 2008-05-07 2014-09-23 Sapporo Medical University Method and kit for detection of cancer, and therapeutic agent for cancer
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
EP2191834A1 (en) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Compositions and methods for treating retrovirus infections
LU91545B1 (en) 2009-03-27 2010-09-28 Univ Luxembourg Mirna as a prognostic diagnostic biomarker and therapeutic agent for breast cancer and other human associated pathologies
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
FR2948687B1 (fr) * 2009-07-29 2015-09-04 Centre Nat Rech Scient Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
US20120238459A1 (en) * 2009-09-07 2012-09-20 Yoshiki Murakami Method for predicting therapeutic effect on chronic hepatitis c
US8846631B2 (en) 2010-01-14 2014-09-30 Regulus Therapeutics Inc. MicroRNA compositions and methods
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
US9272053B2 (en) 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
US20130149320A1 (en) * 2010-05-31 2013-06-13 Centre National De La Recherche Scientifique Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
WO2012041959A1 (en) 2010-09-30 2012-04-05 University Of Zurich Treatment of b-cell lymphoma with microrna
CN102031309A (zh) * 2010-11-30 2011-04-27 华东师范大学 miRNA-34c化合物作为脑胶质瘤标志物的应用
CN105969773A (zh) 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
JP2014506791A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−３４の合成模倣体
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US20130028956A1 (en) 2011-07-29 2013-01-31 Andre Fischer Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US20150292023A1 (en) * 2011-12-01 2015-10-15 Ohio State Innovation Foundation Materials and Methods Related to NSAID Chemoprevention in Colorectal Cancer
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
CN105324119A (zh) * 2013-06-16 2016-02-10 国立大学法人东京医科齿科大学 具有外显子跳跃效应的双链反义核酸
CN105899663B (zh) * 2013-12-26 2019-07-26 学校法人东京医科大学 用于基因表达控制的人工模拟miRNA及其用途
CN106068324B (zh) 2013-12-27 2020-12-29 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
RU2738421C2 (ru) 2014-10-21 2020-12-14 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
WO2016104775A1 (ja) 2014-12-27 2016-06-30 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
WO2017070516A1 (en) * 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
WO2017152182A1 (en) * 2016-03-04 2017-09-08 Rhode Island Hospital Targeting microrna for cancer treatment
EP3216869B1 (en) 2016-03-09 2019-09-18 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of leukemia
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP4276184A3 (en) 2017-11-09 2023-12-27 Purmx Therapeutics, Inc. Pharmaceutical composition comprising mirna-3140 for use in treating cancer
CN107699565B (zh) * 2017-11-24 2020-05-22 苏州大学 微小rna及其在制备抗肿瘤药物中的应用
CN110791566B (zh) * 2019-10-29 2023-06-27 徐州市中心医院 人shcbp1基因的用途及相关产品
CN111304327B (zh) * 2020-02-24 2024-04-19 宋程 人grpel2基因的用途及相关产品
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN114010523B (zh) * 2021-11-05 2024-04-12 天津穗纳生物医药科技有限公司 皮肤抗衰剂及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177568A1 (en) * 1992-12-07 2002-11-28 Stinchcomb Dan T. Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20070032441A1 (en) * 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1628993A4 (en) 2003-05-16 2010-04-07 Rosetta Inpharmatics Llc METHOD AND COMPOSITIONS FOR RNA INTERFERENCE
US6882555B2 (en) 2003-06-18 2005-04-19 Lattice Semiconductor Corporation Bi-directional buffering for memory data lines
CA2539651A1 (en) 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
ATE452188T1 (de) 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
IL179285A (en) * 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
AU2005250432B2 (en) 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
EP1951263A4 (en) * 2005-11-21 2009-11-18 Johnson & Johnson Res Pty Ltd MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS
US7893975B2 (en) * 2006-10-13 2011-02-22 Apple Inc. System and method for processing images using predetermined tone reproduction curves
US8220277B2 (en) * 2006-11-07 2012-07-17 Tiax Llc Dehumidification method having multiple different refrigeration paths between the reheat and cooling coils
EP2111408A4 (en) 2007-01-17 2010-02-03 Univ Johns Hopkins COMPOSITIONS AND METHODS OF microRNA FOR THE TREATMENT OF NEOPLASIA
AU2008220438A1 (en) 2007-02-27 2008-09-04 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
JP2010525826A (ja) 2007-05-03 2010-07-29 ロゼッタ インファーマティックス エルエルシー 癌を治療するためのｍｉｒ３４治療剤を含む組成物

Also Published As

Publication number Publication date
US20100227909A1 (en) 2010-09-09
EP2152722B1 (en) 2016-04-27
EP2152722A4 (en) 2011-12-28
US8399248B2 (en) 2013-03-19
WO2008137862A2 (en) 2008-11-13
US8378088B2 (en) 2013-02-19
WO2008137862A3 (en) 2009-02-19
EP2152722A2 (en) 2010-02-17
WO2008137867A3 (en) 2009-04-16
US20110105583A1 (en) 2011-05-05
WO2008137867A2 (en) 2008-11-13
CA2686165A1 (en) 2008-11-13
JP2010525826A (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
EP2152722B1 (en) Compositions comprising mir34 therapeutic agents for treating cancer
Krützfeldt et al. Silencing of microRNAs in vivo with ‘antagomirs’
Jia et al. Expression, regulation and roles of miR‐26a and MEG3 in tongue squamous cell carcinoma
WO2009131887A2 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
US8232085B2 (en) Isoform of bruton's tyrosine kinase (BTK) protein
Tian et al. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis
US20110118337A1 (en) Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
US20090136957A1 (en) Methods and compositions for regulating cell cycle progression via the miR-106B family
Zheng et al. miR‐21 downregulates the tumor suppressor P12CDK2AP1 and Stimulates Cell Proliferation and Invasion
US9056135B2 (en) MicroRNA biomarkers for human breast and lung cancer
CN105705640A (zh) 抑制lncRNA用于治疗黑素瘤
WO2008088858A2 (en) Compositions and methods featuring micronas for treating neoplasia
CN101376910B (zh) 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
WO2012109466A2 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
Xie et al. MDM4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells
JP2011093892A (ja) がん抑制的マイクロｒｎａを含む腫瘍増殖抑制剤
WO2011111715A1 (ja) 細胞周期を制御する核酸
JP4851940B2 (ja) がんまたは糖尿病治療のための医薬組成物
CN118389680B (zh) 口腔鳞癌相关生物标志物及诊断和治疗方法
US20120108457A1 (en) Mir-211 expression and related pathways in human melanoma
KR102293777B1 (ko) 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법
Mourad MicroRNA Regulation of hERG-Related Current: Potential Role in Heart Failure-Associated Arrhythmias
Chen MicroRNA-193b functions as a tumor suppressor in malignant melanoma
Pedersen MicroRNA 21’s effect on apoptosis and insulin secretion in insulin secreting β-cell lines.

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period